Treatment | Vehicle | RacL11 | LPS |
---|
Monocyte-enriched* | 0 | 2.36 ± 0.05** | 2.78 ± 0.07** |
Monocyte-depleted | 0 | 0 | 0 |
- Monocytes were purified using a murine anti-equine CD14 antibody and procoagulant activity was measured in monocyte-enriched and -depleted PBMC fractions with a two-stage amidolytic assay 4 h after infection with RacL11 (MOI of 5), using LPS (10 ng/mL) positive and vehicle (PBS) negative controls. Data represents the mean ± SD of FXa generation (nM) from 3 horses.
- * p < 0.05 comparing all treatments for monocyte-enriched cells.
- ** p < 0.05 versus the monocyte-depleted fraction.